Evotec Appoints Ashiq H. Khan CCO
Analysis based on 7 articles · First reported Apr 01, 2026 · Last updated Apr 01, 2026
The appointment of Ashiq H. Khan as Chief Commercial Officer of Evotec is expected to positively impact Evotec's growth strategy and commercial organization. This move signals Evotec's commitment to strengthening its leadership in drug discovery and development.
Evotec announced the appointment of Dr. Ashiq H. Khan as its EVP Global Head, Chief Commercial Officer, effective April 1, 2026. Dr. Khan brings over 15 years of international leadership experience in biotech, CRO, and AI-driven platform businesses, with a track record of closing over $7 billion in agreements. In his new role, Ashiq H. Khan will lead the development of a globally integrated commercial organization to enhance customer value and drive sustainable growth for Evotec. Christian Wojczewski, CEO of Evotec, highlighted Ashiq H. Khan's expertise in innovative areas like robotics and artificial intelligence as crucial for Evotec's transformation. Prior to joining Evotec, Ashiq H. Khan held leadership positions at Iktos, Proteros Biostructures, and Schrödinger, Inc.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard